United States officials granted full approval to a closely watched Alzheimer’s drug on Thursday, clearing the way for the government-run Medicare and other insurance plans to begin covering the treatment for people with the brain-robbing disease.
The Food and Drug Administration (FDA) endorsed the IV drug Leqembi for patients with mild dementia and other symptoms caused by early Alzheimer’s disease. It is the first medicine that has been convincingly shown to modestly slow the cognitive decline caused by Alzheimer’s.
